ClinicalTrials.gg
CompletedNCT00002319Updated Jun 24, 2005

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

A Phase 3 interventional study of Doxorubicin hydrochloride (liposomal) in Sarcoma, Kaposi and HIV Infections, sponsored by Sequus Pharmaceuticals. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Sequus Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Sarcoma, Kaposi with a site in United States — 13 open to participants now, 18 under way, none of them phase 3. Sarcoma, Kaposi · United States.

Phase 3
7 of 115
none open now
Registered
6th of 115
by date
Lead sponsor
4 of 115
Sequus Pharmaceuticals

Among the 115 studies in Sarcoma, Kaposi with a site in United States, this one is one of 7 in phase 3, and was the 6th registered.

Sarcoma, Kaposi

161 studies on the registry are indexed under Sarcoma, Kaposi; 24 are open to participants now.

Browse Sarcoma, Kaposi studies →

Open to participants now

13 of the 115 studies in Sarcoma, Kaposi with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Sarcoma, Kaposi studies recruiting now, 11 (52%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Sarcoma, Kaposi with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in controlled studies of limited duration, or those with KS who discontinued treatment with another Kaposi's sarcoma therapy because of inadequate efficacy or unacceptable toxicity. To provide a defined protocol for Kaposi's sarcoma patients for whom DOX-SL therapy is indicated.

Read the detailed description

Patients receive DOX-SL every 3 weeks for a maximum of 20 cycles (including any cycles from a previous DOX-SL study). KS lesions are evaluated prior to administration of each treatment, at the end of the final treatment cycle, and at 4 weeks following the end of the final treatment. Patients who respond will be followed every 2 months for up to 1 year. Study treatment may be interrupted for up to 4 months because of complete response, development of opportunistic infections, or adverse drug effects.

03

Conditions studied

  • Sarcoma, Kaposi
  • HIV Infections

Keywords

  • Sarcoma, Kaposi
  • Liposomes
  • Doxorubicin
  • Acquired Immunodeficiency Syndrome
  • Drug Carriers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

  • Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy provided these doses have been stable for at least 1 month.
  • Maintenance therapy for tuberculosis, fungal, and herpes infections.
  • Therapy for new episodes of tuberculosis, fungal, and herpes infections except with potentially myelotoxic chemotherapy.
  • Foscarnet or ganciclovir for CMV infection.
  • Colony stimulating factors and erythropoietin.

Patients must have:

  • Moderate to severe AIDS-related Kaposi's sarcoma.
  • Documented anti- antibody.
  • No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganisms (if under treatment with myelotoxic drugs).

NOTE:

  • Eligible KS patients include those who have discontinued therapy in the control arm of a DOX-SL KS study because of side effects or inadequate efficacy OR other KS patients for whom DOX-SL is believed to be indicated. Patients must not be eligible for other Liposome Technology protocols comparing DOX-SL with established therapies.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • cardiac disease.
  • Confusion or disorientation.

Concurrent Medication:

Excluded:

  • Other cytotoxic cancer chemotherapy.

Patients with the following prior conditions are excluded:

  • Prior neoplasms treated with extensive chemotherapy that, in the investigator's opinion, has led to an irreversibly compromised marrow function.
  • History of idiosyncratic or allergic reaction to anthracyclines.
  • History of major psychiatric illness.

Prior Medication:

Excluded within the past 4 weeks:

  • Cytotoxic chemotherapy (other than in a qualifying Liposome Technology protocol).
  • Interferon treatment.

Prior Treatment:

Excluded within the past 3 weeks:

  • Radiation or electron beam therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
None (open label)
06

Study locations

33 sites
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Pacific Oaks Med Group
    Beverly Hills, California 90211, United States
  • Hematology - Oncology Med Group of San Fernando Valley
    Encino, California 91436, United States
  • Dr Becky Miller
    Los Angeles, California 90048, United States
  • Apogee Med Group
    San Diego, California 92103, United States
  • UCSF - San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • UCSF
    San Francisco, California 94117, United States
  • San Francisco Veterans Administration Med Ctr
    San Francisco, California 94121, United States
  • UCSF
    San Francisco, California 941430324, United States
  • Pacific Oaks Med Group
    Sherman Oaks, California 91403, United States
  • Dr Mahmoud Mustafa
    Washington, District of Columbia 20037, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • H Lee Moffit Cancer Ctr and Research Institute
    Tampa, Florida 33612, United States
  • American Med Research Institute
    Atlanta, Georgia 30329, United States
  • Infectious Disease Rsch Consortium of GA / SE Clin Resources
    Atlanta, Georgia 30345, United States
  • Northwestern Med Faculty Foundation
    Chicago, Illinois 60611, United States
  • Rush Presbyterian Med College
    Chicago, Illinois 60612, United States
  • Illinois Masonic Med Ctr / The Cancer Ctr
    Chicago, Illinois 60657, United States
  • Henry Ford Hosp
    Detroit, Michigan 48202, United States
  • Washington Univ
    St. Louis, Missouri 63108, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Saint Vincent's Hosp and Med Ctr
    New York, New York 10011, United States
  • New York Univ Med Ctr
    New York, New York 10016, United States
  • Mem Sloan - Kettering Cancer Ctr
    New York, New York 10021, United States
  • Saint Luke's - Roosevelt Hosp Ctr
    New York, New York 10023, United States
  • Mount Sinai Med Ctr
    New York, New York 10029, United States
  • Graduate Hosp / Tuttleman Cancer Ctr
    Philadelphia, Pennsylvania 19146, United States
  • Comprehensive Care Ctr
    Dallas, Texas 75235, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Immunological Institute
    Houston, Texas 77054, United States
  • Twelve Oaks Hosp
    Houston, Texas 77074, United States
  • Virginia Mason Research Center / Clinical Trial Unit
    Seattle, Washington 98101, United States
07

References and documents

Publications

  • Jablonowski H, Szelenyi H, Armbrecht C, Mauss S, Niederau C, Strohmeyer G. Liposomal doxorubicin--a new formulation for the treatment of Kaposi's sarcoma: a study on safety and efficacy in AIDS patients. Int Conf AIDS. 1993 Jun 6-11;9(1):397 (abstract no PO-B12-1573)
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002319
Lead sponsor
Sequus Pharmaceuticals
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion